With the emergence of a critical pathogenic role of IgE in promoting EAE and MS, therapies against MS could be developed to neutralize IgE or block IgE activity, such as the use of omalizumab in other autoimmune disorders (109). This evidence concerns the gene IGHE and Autoimmunity.